← Iovance Biotherapeutics, Inc. (IOVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Iovance Biotherapeutics, Inc. (IOVA)
Biological Products, (No Diagnostic Substances) · market cap $4.7B · as of 2026-08-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Iovance Biotherapeutics is a commercial-stage cell therapy company built around tumor-infiltrating lymphocyte (TIL) therapy, with lead product Amtagvi (lifileucel) already on the market for advanced melanoma and a Phase 3 confirmatory/label-expansion program combining lifileucel with pembrolizumab. FY2025 revenue reached $264M (up from $164M in 2024), but the company remains deeply unprofitable (-$391M net) and is running with only ~8 months of cash at $196.5M — the central tension in the story.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer |
| IOV-3001 | Phase 2 | Unresectable Melanoma |
| IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia |
| LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
| Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma |
| Lifileucel | Phase 2 | Endometrial Cancer |
| IOV-4001 | Phase 2 | Unresectable Melanoma |
Price & technical context
3-month
+230.2%
6-month
+312.5%
12-month
+555.8%
52-wk range
$1.81–$14.82
vs 50-day MA
+75.9%
vs 200-day MA
+204.6%
Realized vol
97.8%
Max drawdown
-86.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IOVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.